Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Regulatory and Compliance Updates news
(page 6)
11 May 2026
GSK partners with Sino Biopharmaceutical (CTTQ) for exclusive China launch of bepirovirsen
Potential first-in-class CHB treatment under priority review in China; deal provides access to 5,000+ medical centres at launch, local import/distribution, hospital access and initial 5.5-yr supply.
9 May 2026
Uniper demolishes Scholven towers D & E for H2-ready CCGT
Two 114 m cooling towers were demolished at 11:00; ~15,000 t of concrete will be recycled for site backfill. Demolition used a coordinated safety plan; no resident evacuations.
8 May 2026
argenx: FDA expands VYVGART/VYVGART Hytrulo approval to all adult gMG patients
Phase-3 ADAPT SERON: VYVGART showed rapid, significant, sustained improvements across anti-MuSK, anti-LRP4 and triple-seronegative gMG; safety consistent; IV/SC options; access support.
8 May 2026
Clariant Q1 2026: Resilient performance amid Middle East conflict
Q1 sales down 2% (CHF918m); EBITDA margin fell to 17.5% (-130bp). Free cash-flow conversion rose to 54%. CHF80m savings program on track; 2026 guidance unchanged amid conflict
8 May 2026
MOL Group Q1 2026: USD 212m profit amid supply disruptions and price controls
Higher hydrocarbon prices lifted upstream; production 95.5 mboepd. Downstream hit by lower refining volumes and feedstock scarcity; Rijeka delayed coker opened. Consumer services and circulars rose.
7 May 2026
argenx Q1 2026 Financial Results & Business Update
Q1 product sales $1.3B (+63% YoY); profit $366M; PDUFA May 10 for seronegative gMG; VYVGART label expansions, multiple pipeline readouts in 2026–27; cash $4.9B
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
7 May 2026
EU, Brazil and China launch Open Coalition on Compliance Carbon Markets
New coalition to strengthen domestic carbon markets: improve MRV, accounting, transparency and offsets. Open to nations with national compliance schemes; New Zealand and Germany have joined.
7 May 2026
PureCycle Achieves A3 CosPaTox Rating for Leave‑On Cosmetic‑Grade PureFive Resin
Independent study shows dissolution recycling converts post‑consumer polypropylene into A3 leave‑on cosmetic grade resin commercially, removing contaminants, retaining performance and lowering CO₂
7 May 2026
Moeve Q1 2026 Clean CCS EBITDA €506m, ramps Spain energy-transition capex
Q1 net income €147m; capex €272m (69% to energy transition); operating cash flow €283m; FID for 300MW Andalusian green hydrogen; non-binding talks with Galp; net debt €2.56bn (1.6x).
7 May 2026
Indaver pauses processing of highly PFAS-contaminated waste
Authorities demand extra measurements and monitoring after limited historical soil contamination; four PFAS streams will be suspended while datasets and remediation checks are expanded.
7 May 2026
UPM, Michelman and BOBST launch EU‑compliant bio‑based paper packaging concepts
Two paper packaging concepts for EU SUPD: fiber papers with bio-based coatings giving moisture/mineral-oil and oxygen barriers, wide heat-seal window, recyclable/compostable, production-ready.
6 May 2026
PureCycle Technologies Q1 2026 Results
Ironton turnaround finished early/under budget; record 8.4M lb production (~10M lb feedstock); 5th consecutive revenue growth; two P&G approvals; Q1 net loss $33.4M; liquidity $131M.
5 May 2026
Merck acquires Terns Pharmaceuticals
Adds TERN‑701, an oral allosteric BCR::ABL1 TKI with FDA Breakthrough for certain CML patients. Bought via $53/share tender and merger; ~$5.8B R&D charge; Terns now delisted and private.
5 May 2026
LANXESS Lewatit MDS TP 108 Removes >99.9% PFAS at Chemours
Selective monodisperse ion-exchange resin removed >99.9% of fluorinated organics in wastewater, targeting short-chain PFAS via a 3-stage RO, carbon, resin cascade; spent resin incinerated.
4 May 2026
BASF Engineering Plastics Certified to EN 45545 Railway Standard
Ultramid and Ultradur grades certified to EN 45545 for railway E&E. Halogen‑free flame retardants (intumescent, Mg(OH)2), color‑independent approval and defined thicknesses for design freedom.
4 May 2026
UPM and BASF advance recyclable fiber-based packaging
Barrier papers paired with Joncryl HPB coatings enable high-performance, recyclable fiber-based packaging; samples to be shown at interpack 2026, supporting design-for-recycling rules.
2 May 2026
thyssenkrupp AG, Jindal pause talks on thyssenkrupp Steel stake
Steel unit's outlook improves after restructuring and IG Metall agreement; EU trade protections and CBAM increase stability. Goal: autonomous, profitable steel business; parent may keep minority stake
1 May 2026
Novo Nordisk launches Ozempic pill — FDA‑approved oral semaglutide for adults with type 2 diabetes
Tablets (1.5, 4, 9 mg) debut in US May 4. Reformulated from Rybelsus, available at 70,000+ pharmacies; insurance from $25; self-pay $149/199/299/month. Approved to reduce cardiovascular events
30 April 2026
Messer 2025 sustainability report — 2% GHG reduction
Year‑on‑year 2% reduction in market‑based GHGs from operations; renewable electricity and solar installs; ZeCarb carbon services; independent limited assurance for materiality and select KPIs.
30 April 2026
MOL to acquire O&GD upstream assets in Hungary
Buys 51% stakes in three Central Hungary concessions (~0.7 mboepd) plus Eastern Hungary assets (~0.2 mboepd), adding ~0.9 mboepd to group production; closing Q3 2026, subject to approvals.
30 April 2026
Uniper receives preliminary approval for hydrogen-ready CCGT Unit 8 at Staudinger
Regional authority grants preliminary approval for hydrogen-ready 890 MW CCGT; feasibility, emissions and habitat issues resolved; first partial permit due Q3 2026; project to enter capacity auctions
30 April 2026
Petrobras posts 1Q26 own production record of 3.23 MMboed
Ramp-up of multiple FPSOs and 10 new wells drove production gains (3.7% QoQ, 16.1% YoY); operated production 4.65 MMboed. Refining utilization, S10 diesel output and logistics records; LPG imports fell.
30 April 2026
Lhyfe to supply green hydrogen to BMW Group’s Steyr R&D centre
Multi-year deal to supply green hydrogen to an Austrian R&D site for development and validation of third-gen fuel-cell systems; first Austrian deliveries via bulk transport; RFNBO-certified.
30 April 2026
Eli Lilly Q1 2026: Revenue up 56%, raises full‑year guidance
EPS jumped ~170% reported (~156% non‑GAAP); volume growth offset lower realized prices; FDA approved oral GLP‑1 Foundayo; positive Phase‑3 readouts; four acquisitions announced
30 April 2026
Merck & Co Q1 2026 Results — Sales Growth, Regulatory Approvals and Clinical Milestones
Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16
29 April 2026
Biosimilars: stricter expectations for elastomeric closures
Originator-level assessment required (functionality, E&L, CCI). Supplier data can't replace system-level testing. Risks: format migration, dual-market filings. Adopt platform approach; decide early.
29 April 2026
SABIC Q1 2026 results
Q1: adjusted EBITDA +25% to SAR4.15bn; revenue -6% to SAR26.15bn; adjusted net income SAR816m; realized $220m recurring EBITDA savings; divestments announced; urea capacity could rise 54%
29 April 2026
Novo Nordisk: Denecimig (Mim8) reduces annualised bleeding rate in haemophilia A regardless of inhibitor status
Denecimig (Mim8) cut annualised bleeding rates in haemophilia A (with/without inhibitors) in Phase 3 FRONTIER2 for once-monthly/weekly dosing; well tolerated, no thromboembolic events
29 April 2026
GSK Q1 2026 — Specialty Medicines Drive Growth
Q1 sales £7.6bn (+5% CER); Specialty Medicines £3.2bn (+14%). Core operating profit +10%, Core EPS +9%. Strong cash generation; 17p Q1 dividend. 2026 guidance and >£40bn 2031 target reaffirmed.
29 April 2026
UPM approves Plywood demerger to create listed WISA Group
Board approved plan to spin off a business into a new listed company; EGM approval pending; 1:1 share distribution; target completion Oct 31, 2026; listing expected early Nov 2026.
← Previous
Next →
